×
S&P 500   3,818.67 (-0.17%)
DOW   30,868.23 (-0.74%)
QQQ   285.80 (+1.30%)
AAPL   140.97 (+1.47%)
MSFT   262.07 (+0.96%)
META   167.24 (+4.51%)
GOOGL   2,257.44 (+3.80%)
AMZN   113.49 (+3.59%)
TSLA   693.72 (+1.75%)
NVDA   148.74 (+2.42%)
NIO   21.99 (+2.95%)
BABA   118.21 (+1.91%)
AMD   74.83 (+1.57%)
MU   56.51 (+5.33%)
CGC   2.69 (-4.27%)
T   21.09 (-1.03%)
GE   61.34 (-3.46%)
F   11.10 (-1.94%)
DIS   96.78 (+0.67%)
AMC   12.68 (-6.28%)
PFE   51.32 (-1.89%)
PYPL   74.26 (+4.01%)
NFLX   184.02 (+2.26%)
S&P 500   3,818.67 (-0.17%)
DOW   30,868.23 (-0.74%)
QQQ   285.80 (+1.30%)
AAPL   140.97 (+1.47%)
MSFT   262.07 (+0.96%)
META   167.24 (+4.51%)
GOOGL   2,257.44 (+3.80%)
AMZN   113.49 (+3.59%)
TSLA   693.72 (+1.75%)
NVDA   148.74 (+2.42%)
NIO   21.99 (+2.95%)
BABA   118.21 (+1.91%)
AMD   74.83 (+1.57%)
MU   56.51 (+5.33%)
CGC   2.69 (-4.27%)
T   21.09 (-1.03%)
GE   61.34 (-3.46%)
F   11.10 (-1.94%)
DIS   96.78 (+0.67%)
AMC   12.68 (-6.28%)
PFE   51.32 (-1.89%)
PYPL   74.26 (+4.01%)
NFLX   184.02 (+2.26%)
S&P 500   3,818.67 (-0.17%)
DOW   30,868.23 (-0.74%)
QQQ   285.80 (+1.30%)
AAPL   140.97 (+1.47%)
MSFT   262.07 (+0.96%)
META   167.24 (+4.51%)
GOOGL   2,257.44 (+3.80%)
AMZN   113.49 (+3.59%)
TSLA   693.72 (+1.75%)
NVDA   148.74 (+2.42%)
NIO   21.99 (+2.95%)
BABA   118.21 (+1.91%)
AMD   74.83 (+1.57%)
MU   56.51 (+5.33%)
CGC   2.69 (-4.27%)
T   21.09 (-1.03%)
GE   61.34 (-3.46%)
F   11.10 (-1.94%)
DIS   96.78 (+0.67%)
AMC   12.68 (-6.28%)
PFE   51.32 (-1.89%)
PYPL   74.26 (+4.01%)
NFLX   184.02 (+2.26%)
S&P 500   3,818.67 (-0.17%)
DOW   30,868.23 (-0.74%)
QQQ   285.80 (+1.30%)
AAPL   140.97 (+1.47%)
MSFT   262.07 (+0.96%)
META   167.24 (+4.51%)
GOOGL   2,257.44 (+3.80%)
AMZN   113.49 (+3.59%)
TSLA   693.72 (+1.75%)
NVDA   148.74 (+2.42%)
NIO   21.99 (+2.95%)
BABA   118.21 (+1.91%)
AMD   74.83 (+1.57%)
MU   56.51 (+5.33%)
CGC   2.69 (-4.27%)
T   21.09 (-1.03%)
GE   61.34 (-3.46%)
F   11.10 (-1.94%)
DIS   96.78 (+0.67%)
AMC   12.68 (-6.28%)
PFE   51.32 (-1.89%)
PYPL   74.26 (+4.01%)
NFLX   184.02 (+2.26%)
NASDAQ:CBIO

Catalyst Biosciences Stock Forecast, Price & News

$1.78
-0.01 (-0.56%)
(As of 07/5/2022 02:50 PM ET)
Add
Compare
Today's Range
$1.74
$1.81
50-Day Range
$0.36
$1.79
52-Week Range
$0.35
$5.20
Volume
10,044 shs
Average Volume
2.73 million shs
Market Capitalization
$56.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.33

Catalyst Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
653.3% Upside
$13.33 Price Target
Short Interest
Healthy
6.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.38
Upright™ Environmental Score
News Sentiment
0.83mentions of Catalyst Biosciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.24) to ($0.56) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.09 out of 5 stars

Medical Sector

388th out of 1,428 stocks

Pharmaceutical Preparations Industry

181st out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Catalyst Biosciences logo

About Catalyst Biosciences (NASDAQ:CBIO) Stock

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

CBIO Stock News Headlines

Recap: Catalyst Biosciences Q1 Earnings
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CBIO
CUSIP
87611R30
Employees
56
Year Founded
2003

Company Calendar

Last Earnings
5/09/2022
Today
7/05/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$13.33
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+649.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33333333333333
Research Coverage
3 Analysts

Profitability

Net Income
$-87,930,000.00
Net Margins
-1,200.77%
Pretax Margin
-1,200.77%

Debt

Sales & Book Value

Annual Sales
$7.34 million
Book Value
$1.31 per share

Miscellaneous

Free Float
30,558,000
Market Cap
$56.03 million
Optionable
Optionable
Beta
1.51

Social Links















Catalyst Biosciences Frequently Asked Questions

Should I buy or sell Catalyst Biosciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Catalyst Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CBIO, but not buy additional shares or sell existing shares.
View analyst ratings for Catalyst Biosciences
or view top-rated stocks.

What is Catalyst Biosciences' stock price forecast for 2022?

3 Wall Street research analysts have issued 12 month price targets for Catalyst Biosciences' shares. Their CBIO stock forecasts range from $4.00 to $18.00. On average, they expect Catalyst Biosciences' stock price to reach $13.33 in the next year. This suggests a possible upside of 653.3% from the stock's current price.
View analysts' price targets for Catalyst Biosciences
or view top-rated stocks among Wall Street analysts.

How has Catalyst Biosciences' stock performed in 2022?

Catalyst Biosciences' stock was trading at $0.9140 on January 1st, 2022. Since then, CBIO shares have increased by 93.7% and is now trading at $1.77.
View the best growth stocks for 2022 here
.

When is Catalyst Biosciences' next earnings date?

Catalyst Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Catalyst Biosciences
.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences, Inc. (NASDAQ:CBIO) issued its quarterly earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.10. The biopharmaceutical company earned $0.79 million during the quarter. Catalyst Biosciences had a negative trailing twelve-month return on equity of 149.54% and a negative net margin of 1,200.77%.
View Catalyst Biosciences' earnings history
.

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Catalyst Biosciences shares reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the following people:
  • Dr. Nassim Usman Ph.D., Pres, CEO & Director (Age 62, Pay $613.11k)
  • Ms. Seline E. Miller CPA, Sr. VP of Fin., Interim Chief Financial & Principal Accounting Officer
  • Dr. Grant Blouse M.Sc., Ph.D., Chief Scientific Officer
  • Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D., Consultant (Age 68, Pay $434.21k)
  • Ms. Ana Kapor, Sr. Director of Investor Relations & Corp. Communications
  • Dr. Tom Knudsen D.V.M., Ph.D., Sr. VP of Corp. Devel.

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Celsion (CLSN).

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

How do I buy shares of Catalyst Biosciences?

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $1.77.

How much money does Catalyst Biosciences make?

Catalyst Biosciences (NASDAQ:CBIO) has a market capitalization of $55.72 million and generates $7.34 million in revenue each year. The biopharmaceutical company earns $-87,930,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis.

How many employees does Catalyst Biosciences have?

Catalyst Biosciences employs 56 workers across the globe.

When was Catalyst Biosciences founded?

Catalyst Biosciences was founded in 2003.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The official website for Catalyst Biosciences is www.catalystbiosciences.com. The biopharmaceutical company can be reached via phone at (650) 871-0761, via email at investors@catbio.com, or via fax at 336-480-2107.

This page (NASDAQ:CBIO) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.